Erin Ator Thomson Sells 3,000 Shares of Shattuck Labs, Inc. (NASDAQ:STTK) Stock

Shattuck Labs, Inc. (NASDAQ:STTK) General Counsel Erin Ator Thomson sold 3,000 shares of Shattuck Labs stock in a transaction on Tuesday, June 8th. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00.

Erin Ator Thomson also recently made the following trade(s):

  • On Monday, May 17th, Erin Ator Thomson sold 4,000 shares of Shattuck Labs stock. The shares were sold at an average price of $26.25, for a total transaction of $105,000.00.
  • On Wednesday, April 28th, Erin Ator Thomson sold 5,000 shares of Shattuck Labs stock. The stock was sold at an average price of $35.00, for a total transaction of $175,000.00.
  • On Thursday, April 15th, Erin Ator Thomson sold 7,000 shares of Shattuck Labs stock. The stock was sold at an average price of $30.77, for a total transaction of $215,390.00.

Shares of NASDAQ STTK opened at $28.94 on Friday. The business’s fifty day moving average price is $29.35. Shattuck Labs, Inc. has a 1 year low of $17.51 and a 1 year high of $60.52. The stock has a market capitalization of $1.21 billion and a P/E ratio of -12.26.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings results on Monday, May 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.11. The firm had revenue of $2.27 million for the quarter. On average, analysts forecast that Shattuck Labs, Inc. will post -1.37 EPS for the current year.

A number of equities analysts recently commented on the stock. Berenberg Bank initiated coverage on shares of Shattuck Labs in a research note on Wednesday, April 14th. They set a “buy” rating and a $47.00 price target for the company. Zacks Investment Research upgraded shares of Shattuck Labs from a “sell” rating to a “hold” rating in a report on Tuesday, May 18th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $45.60.

A number of large investors have recently bought and sold shares of STTK. Strs Ohio acquired a new position in Shattuck Labs during the fourth quarter worth $167,000. Victory Capital Management Inc. acquired a new position in Shattuck Labs during the fourth quarter worth $4,094,000. BlackRock Inc. acquired a new position in Shattuck Labs during the fourth quarter worth $45,082,000. New York State Common Retirement Fund acquired a new position in Shattuck Labs during the fourth quarter worth $535,000. Finally, Alliancebernstein L.P. acquired a new position in Shattuck Labs during the fourth quarter worth $204,000. Institutional investors own 55.96% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

Featured Article: What is the downside to momentum investing?

Insider Buying and Selling by Quarter for Shattuck Labs (NASDAQ:STTK)

Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.